Utility of Molecular Testing for Identifying Targetable Molecular Alterations and Supporting a Diagnosis of Anaplastic Thyroid Carcinoma on Core Needle Biopsy

Background Molecular testing of anaplastic thyroid carcinoma (ATC) is recommended by the American Thyroid Association early in diagnosis to support a diagnosis of ATC in specimens of ambiguous morphology/immunophenotype and enable possible alternative systemic treatment options. Ideally, molecular testing should be performed on the initial diagnostic pathology sample, frequently the core needle biopsy (CNB) specimen, despite potential concerns about tissue sufficiency. This study aimed to determine the practical feasibility and treatment implications of performing molecular testing, primarily in-house next-generation sequencing (NGS), on CNB with ATC. Methods This study was a retrospective review of CNB performed within our institution in which a diagnosis of ATC was considered. Molecular and immunohistochemistry (IHC) results were reviewed and, if not initially ordered, performed on available tissue. Results In a cohort of 24 specimens, molecular testing was successfully performed on all specimens; however, tissue scarcity limited molecular and IHC analysis for 5 specimens. Mutations in ATC-associated genes were identified in all specimens, including BRAF p.V600E (58%), RAS family (21%), and TP53 (38%). NGS testing also enabled the evaluation of microsatellite instability (MSI; 0% high), tumor mutational burden (TMB; 9% high), and a number of other potential biomarkers. Although BRAF V600E IHC demonstrated 100% sensitivity and specificity after blinded expert retrospective review, 20% of initial IHC interpretations were incorrectly or ambiguously categorized, highlighting the significant inter-observer variability associated with BRAF IHC interpretation. Conclusion Molecular testing on CNB is feasible and provides broader biomarker coverage with greater consistency and less interpretative variability than IHC.

Authors

Institutions

Publication Details

Journal
International Journal of Surgical Pathology
Published
2026-11-13
DOI
https://doi.org/10.1177/10668969261493450
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Utility of Molecular Testing for Identifying Targetable Molecular Alterations and Supporting a Diagnosis of Anaplastic Thyroid Carcinoma on Core Needle Biopsy

Eric Vail, Bonnie Lei Balzer, Xuemo Fan, Cedric Bailey et al.
1 links
International Journal of Surgical Pathology
Thyroid Cancer Diagnosis and Treatment
article

Utility of Molecular Testing for Identifying Targetable Molecular Alterations and Supporting a Diagnosis of Anaplastic Thyroid Carcinoma on Core Needle Biopsy

Eric Vail, Bonnie Lei Balzer, Xuemo Fan, Cedric Bailey, Allen S. Ho, Matthew George Gayhart, Matthew T. Leong, Wyleen Kniola
article en

Abstract

Background Molecular testing of anaplastic thyroid carcinoma (ATC) is recommended by the American Thyroid Association early in diagnosis to support a diagnosis of ATC in specimens of ambiguous morphology/immunophenotype and enable possible alternative systemic treatment options. Ideally, molecular testing should be performed on the initial diagnostic pathology sample, frequently the core needle biopsy (CNB) specimen, despite potential concerns about tissue sufficiency. This study aimed to determine the practical feasibility and treatment implications of performing molecular testing, primarily in-house next-generation sequencing (NGS), on CNB with ATC. Methods This study was a retrospective review of CNB performed within our institution in which a diagnosis of ATC was considered. Molecular and immunohistochemistry (IHC) results were reviewed and, if not initially ordered, performed on available tissue. Results In a cohort of 24 specimens, molecular testing was successfully performed on all specimens; however, tissue scarcity limited molecular and IHC analysis for 5 specimens. Mutations in ATC-associated genes were identified in all specimens, including BRAF p.V600E (58%), RAS family (21%), and TP53 (38%). NGS testing also enabled the evaluation of microsatellite instability (MSI; 0% high), tumor mutational burden (TMB; 9% high), and a number of other potential biomarkers. Although BRAF V600E IHC demonstrated 100% sensitivity and specificity after blinded expert retrospective review, 20% of initial IHC interpretations were incorrectly or ambiguously categorized, highlighting the significant inter-observer variability associated with BRAF IHC interpretation. Conclusion Molecular testing on CNB is feasible and provides broader biomarker coverage with greater consistency and less interpretative variability than IHC.

International Journal of Surgical Pathology
Cedars-Sinai Medical Center (US)
Cedars-Sinai Medical Center
Good health and well-being
Thyroid Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon